See more : Belgravia Hartford Capital Inc. (BLGV.CN) Income Statement Analysis – Financial Results
Complete financial analysis of RxElite, Inc. (RXEI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of RxElite, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Rome Resources Plc (RMR.L) Income Statement Analysis – Financial Results
- Sonoco Products Company (SON) Income Statement Analysis – Financial Results
- Shanghai Sinotec (Group) Co., Ltd. (603121.SS) Income Statement Analysis – Financial Results
- Steinhoff International Holdings N.V. (SNH.SW) Income Statement Analysis – Financial Results
- TotalEnergies SE (TTE.PA) Income Statement Analysis – Financial Results
RxElite, Inc. (RXEI)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.piramalcriticalcare.com
About RxElite, Inc.
RxElite, Inc. engages in the development, manufacture, and marketing of generic prescription drug products in specialty generic markets. Its products include Sterile Liquid Dose products that consist of generic ophthalmic products in unit and multi-dose presentations, sterile unit dose inhalation respiratory products, and injectable drugs. The company, through its subsidiaries, also manufactures active pharmaceutical ingredients for pharmaceutical companies in the United States, Europe, and Asia. Its customers include hospitals and hospital group purchasing organizations, national and regional wholesalers, direct retail pharmacy stocking chains, homecare companies, and outpatient surgery centers and ambulatory care clinics. The company has partnership agreements with Stason Pharmaceuticals, Inc.; Alkem Laboratories Limited; and Zach Systems S.p.A. RxElite is headquartered in Meridian, Idaho. RxElite Inc. operates as a subsidiary of Piramal Healthcare Ltd.
| Metric | 2007 | 2006 | 2005 | 2004 |
|---|---|---|---|---|
| Revenue | 2.81M | 1.18M | 966.49K | 835.08K |
| Cost of Revenue | 2.67M | 434.59K | 449.49K | 0.00 |
| Gross Profit | 144.00K | 741.95K | 517.00K | 835.08K |
| Gross Profit Ratio | 5.12% | 63.06% | 53.49% | 100.00% |
| Research & Development | 3.15M | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 9.08M | 597.97K | 552.91K | 0.00 |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 12.42M | 597.97K | 552.91K | 0.00 |
| Cost & Expenses | 15.09M | 1.03M | 1.00M | 0.00 |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 436.97K | 13.60K | 7.32K | 0.00 |
| EBITDA | -16.46M | 157.58K | -28.58K | 835.08K |
| EBITDA Ratio | -254.58% | 13.39% | -2.96% | 100.00% |
| Operating Income | 12.28M | 143.99K | 35.90K | 835.08K |
| Operating Income Ratio | 436.80% | 12.24% | 3.71% | 100.00% |
| Total Other Income/Expenses | -484.30K | 0.00 | -35.90K | -835.08K |
| Income Before Tax | -17.17M | 143.99K | 0.00 | 0.00 |
| Income Before Tax Ratio | -610.52% | 12.24% | 0.00% | 0.00% |
| Income Tax Expense | 4.88M | 50.00K | 0.00 | 34.30K |
| Net Income | -17.17M | 93.99K | -35.90K | -34.30K |
| Net Income Ratio | -610.52% | 7.99% | -3.71% | -4.11% |
| EPS | -0.27 | 0.01 | 0.00 | 0.00 |
| EPS Diluted | -0.27 | 0.01 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 62.43M | 10.47M | 10.00M | 0.00 |
| Weighted Avg Shares Out (Dil) | 62.43M | 10.47M | 10.00M | 0.00 |
Source: https://incomestatements.info
Category: Stock Reports